TTIB-196 U266B1 人外周淋巴細(xì)胞

ATCC 細(xì)胞|細(xì)胞系細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|;細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件|！

ATCC® Number: TIB-196™ Price: $269.00

Designations: U266B1 [

U266]

Depositors: NK Nilsson

Isotype: IgE; lambda light chain

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens （human）

Morphology: lymphoblast

TTIB-196 U266B1 人外周淋巴細(xì)胞

Source: Organ: peripheral blood

Disease: myeloma; plasmacytoma

Cell Type: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; interleukin 6 （interleukin-6, IL-6）

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: transfection host （Nucleofection technology from Lonza）

DNA Profile （STR）: Amelogenin: X,Y

CSF1PO: 12,13

D13S317: 12

D16S539: 10

D5S818: 11,12

D7S820: 11,12

THO1: 5,7

TPOX: 8

vWA: 17

Age: 53 years adult

Gender: male

Comments: U266 cells have been reported to produce human IL-6.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.

Subculturing: Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.

Preservation: culture medium 95%; DMSO, 5%

Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1180: Nilsson K, et al. Established immunoglobulin producing myeloma （IgE） and lymphoblastoid （IgG） cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745

22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060

32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128

TTIB-196 U266B1